Adverse events associated with JAK inhibitors

被引：0
|
作者：
Hoisnard, L. [1 ,2 ,3 ]
Sbidian, E. [1 ,2 ,3 ,4 ]
机构：
[1] Henri Mondor Hosp, AP HP, Federat Hospitalouniv TRUE InnovaTive Rapy ImmUne, Creteil, France
[2] Ctr Invest Clin, INSERM, Creteil, France
[3] Paris Est Creteil Univ UPEC, EA7379, EpiDermE Epidemiol Dermatol & Evaluat Therapeut, Creteil, France
[4] Henri Mondor Hosp, AP HP, Dept Dermatol, Creteil, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2022年 / 36卷
关键词：
RHEUMATOID-ARTHRITIS; TOFACITINIB;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
ACT-006
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [1] Adverse events with JAK inhibitors
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2024, 6 (02): : E71 - E71
  • [2] JAK inhibitors: risk of major adverse cardiovascular events
    Reactions Weekly, 2025, 2052 (1) : 8 - 8
  • [3] JAK-Inhibitors - A Story of Success and Adverse Events
    Wlassits, Rebekka
    Mueller, Mathias
    Fenzl, Karl H.
    Lamprecht, Thomas
    Erlacher, Ludwig
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2024, 16 : 43 - 53
  • [4] Adverse events associated with mTOR inhibitors
    Pallet, Nicolas
    Legendre, Christophe
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (02) : 177 - 186
  • [5] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, L.
    Lebrun-Vignes, B.
    Maury, S.
    Mahevas, M.
    El Karoui, K.
    Roy, L.
    Zarour, A.
    Michel, M.
    Cohen, J. L.
    Amiot, A.
    Claudepierre, P.
    Wolkenstein, P.
    Grimbert, P.
    Sbidian, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 165 - 165
  • [6] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Léa Hoisnard
    Bénédicte Lebrun-Vignes
    Sébastien Maury
    Matthieu Mahevas
    Khalil El Karoui
    Lydia Roy
    Anissa Zarour
    Marc Michel
    José L. Cohen
    Aurélien Amiot
    Pascal Claudepierre
    Pierre Wolkenstein
    Philippe Grimbert
    Emilie Sbidian
    Scientific Reports, 12
  • [7] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, Lea
    Maury, Sebastien
    Mahevas, Matthieu
    El Karoui, Khalil
    Roy, Lydia
    Cohen, Jose L.
    Amiot, Aurelien
    Claudepierre, Pascal
    Grimbert, Philippe
    Sbidian, Emilie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB137 - AB137
  • [8] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, Lea
    Lebrun-Vignes, Benedicte
    Maury, Sebastien
    Mahevas, Matthieu
    El Karoui, Khalil
    Roy, Lydia
    Zarour, Anissa
    Michel, Marc
    Cohen, Jose L.
    Amiot, Aurelien
    Claudepierre, Pascal
    Wolkenstein, Pierre
    Grimbert, Philippe
    Sbidian, Emilie
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [9] Adverse Events Associated With Immune Checkpoint Inhibitors
    Akturk, Halis Kaan
    Michels, Aaron W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (12): : 1219 - 1219
  • [10] OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
    Mendez-Martinez, Silvia
    Calvo, Pilar
    Ruiz-Moreno, Oscar
    Pardinas Baron, Nieves
    Lecinena Bueno, Jesus
    Gil Ruiz, Maria Del Rocio
    Pablo, Luis
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (08): : 1435 - 1450
12345